Ligand Pharmaceuticals Stock (NASDAQ: LGND)

Ligand Pharmaceuticals

LIGAND PHARMACEUTICALS

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Macro,View,Of,Stacks,Of,Gold,Bars

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ADGM

CHRO

LGND

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings

Financial,Analyst,Analysis,Business,Financial,Report,On,Digital,Tablet,During

CLIK

IOTR

Dow Falls Over 1%; US Initial Jobless Claims Decline

Health Care

Asset Sales

Market-Moving Exclusives

Exclusives

General

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals Inc

Press Releases

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Financing

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand to Participate in March Investor Conferences

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand to Participate in May Investor Conferences

Ligand Reports First Quarter 2025 Financial Results

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

PVLA

XOMA

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Indivior

Innoviva

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Liquidia

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pacira BioSciences

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Verona Pharma plc - American Depositary Shares

Comments

Ligand Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell